Benzinga | Aug 25, 2020 08:05AM EDT

Enlivex Announces Allowance Of New US Patent Covering Allocetra Immunotherapy

Nes-Ziona, Israel, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, today announced that the U.S. Patent and Trademark Office issued a notice of allowance for a new patent application covering ALLOCETRATM, the company's immunotherapy product candidate. Upon issuance, the new patent will provide added intellectual property protection, including methods, uses and pharmaceutical compositions. The company expects that this new patent will be issued in the United States during the fourth quarter of 2020.

ALLOCETRATMhas been designed toprovide a novel immunotherapy mechanism of actionthat targets life-threatening clinical indications that are defined as "unmet medical needs", includingorgan dysfunction and acute multiple organ failure associated with Sepsis and COVID-19, as well as treating solid tumors by modulating such tumors' microenvironment.